What is Ability Pharmaceuticals?
Headquartered in the Parc Tecnològic del Vallès, Ability Pharmaceuticals is a specialized biopharmaceutical entity dedicated to addressing significant unmet medical needs in oncology. Since its inception in 2009, the company has focused on the development of innovative targeted therapies, most notably its lead candidate, ABTL0812, which is currently undergoing phase 2 clinical trials. The company's business model centers on high-value R&D, supported by strategic territorial licensing agreements, such as its partnership with SciClone Pharmaceuticals for the Greater China market. By maintaining a lean, research-intensive structure, Ability Pharmaceuticals has established itself as a pivotal player in the Catalan and Spanish biotech ecosystems, bridging the gap between early-stage discovery and commercial-ready therapeutic solutions.
How much funding has Ability Pharmaceuticals raised?
Ability Pharmaceuticals has raised a total of $7.6M across 1 funding round:
Other Financing Round
$7.6M
Other Financing Round (2024): $7.6M with participation from Inveready, CTI Life Sciences Fund, The CDTI, and The European Innovation Council
Key Investors in Ability Pharmaceuticals
Inveready
Inveready is a prominent Spanish financial services firm specializing in investment solutions and wealth management, focusing on small and mid-market segments.
CTI Life Sciences Fund
CTI Life Sciences Fund is a Canadian biotech venture capital firm that focuses on catalyzing innovative assets into scalable companies within the oncology and rare disease sectors.
The CDTI
The CDTI is a Spanish public entity that supports knowledge-based innovation by offering public aid and partially reimbursable financing for R&D projects.
What's next for Ability Pharmaceuticals?
With the recent influx of capital, Ability Pharmaceuticals is poised to advance its preclinical candidate, ABTL0815, while simultaneously pushing ABTL0812 through its current clinical milestones. The strategic roadmap involves deepening its international presence and potentially expanding its licensing portfolio to include additional global markets. As the company matures, the focus will likely shift toward optimizing its clinical trial data to support future regulatory filings and potential commercialization efforts. The continued support from institutional partners like the CDTI and the European Innovation Council suggests a stable path forward, with the company well-equipped to navigate the high-stakes environment of oncology drug development and deliver long-term value to its stakeholders.
See full Ability Pharmaceuticals company page
